Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

The National Parkinson Foundation Awards Four Innovative Research Grants

One Million Dollar Investment in Clinical Research in Parkinson’s Disease

MIAMI — The National Parkinson Foundation (NPF) announced today that it has funded four new grants in Parkinson’s disease (PD) research. The four grants target key scientific questions about gender differences in Parkinson’s, cognition and inflammation.

“When we selected these three focus areas, we chose to target research to help people with Parkinson’s disease today,” said Peter Schmidt, PhD, NPF’s Senior Vice President and Chief Mission Officer.  “These grants, which include both clinical and pre-clinical research, will advance our knowledge in ways that both inform treatment decisions now and inspire research tomorrow.”

NPF funded the following four studies over a two-year period totaling $1 million dollars:

1) Determinants of sex differences in caregiving for Parkinson’s disease: Nabila Dahodwala, MD, University of Pennsylvania, Philadelphia, PA.

Dr. Dahodwala has been awarded a two-year grant to study issues that result in differences in caregiving and to explore whether there may be options to improve caregiving.  Starting with an analysis of data from NPF’s Parkinson’s Outcomes Project, Dr. Dahodwala will study barriers to effective caregiving, starting in a small-scale setting and expanding to understand a large and diverse group.  Drawing on outcomes data, she will design an approach to help clinicians to address issues of caregiving and to engage clinic social workers to improve the lives of both women and men affected by PD.

2) The relationship between microglial activation and β-amyloid deposition in PD-MCI and PD-dementia: Antonio Strafella, MD, PhD, University of Toronto, Toronto, Canada.

In 2010, Dr. Strafella was awarded a grant from NPF to research how patients with mild cognitive impairment differed from those without, at the level of deep brain structures, using advanced imaging techniques. Dr. Strafella will follow up this work looking at inflammation, studying the impact of the Alzheimer’s protein β-amyloid in Parkinson’s.  This study will use an advanced imaging technique, positron emission tomography (PET) scans, to examine how a number of important factors interrelate in the brain.  First, they will look at how the brain’s immune system, which is based on cells called microglia that respond to inflammation in the brain, are activated in patients experiencing cognitive change.  Second, they will look for deposition of β-amyloid to see if this Alzheimer’s protein is linked to this inflammation.  Finally, they will look to see if the brain atrophies in regions where one or both of these signals are found.  A big question is which comes first: the bad proteins or the inflammation?  This study will be based around a new technology: an innovative PET scan tracer that shows where the brain’s immune system is active.

3) Neuroinflammation via T-cell response in Parkinson’s and Lewy body diseases: David Sulzer, PhD, Columbia University, New York, NY.

In this study, Dr. Sulzer explores a radical new hypothesis: could Parkinson’s disease be significantly characterized as an auto-immune disorder, where the cell damage in Parkinson’s is caused more by immune system response than by accumulation of toxic proteins?  Dr. Sulzer’s lab has identified two markers of immune response present in people with Parkinson’s.  While this work is related to the current focus on the key Parkinson’s protein called α-synuclein, it suggests that the greatest impact of this protein may actually be down-stream from its synthesis and misfolding.  By focusing on studying tissue from patients with Parkinson’s and not models, Dr. Sulzer hopes to provide a greater understanding of Parkinson’s.

4) Establishing the link between canonical TGFβ-superfamily signaling and Parkinson’s disease pathophysiology: Paschalis Sideras, PhD, Biomedical Research Foundation Academy, Athens, Greece.

Several processes in the brain, including some inflammatory reactions, are regulated using signaling proteins called transforming growth factor-beta (TGFβ) proteins.  Scientists know that several TGFβ proteins are linked to Parkinson’s disease, but how they are linked is not yet known.  Dr. Sideras will study these regulatory proteins in several mouse models of Parkinson’s, looking for common responses across models that could help inform treatment decisions and future research.  Dr. Sideras hopes that understanding TGFβ will guide strategies to make the dopamine-producing neurons more resistant to PD.

“Three of these NPF-funded grants are focused on the intersection between inflammation in the brain and Parkinson’s disease,” said Ariel Deutch, PhD, chairman of NPF’s Clinical and Scientific Advisory Board (CSAB), who led the grant review. “Until recently, it was thought that the brain lacked an immune response.  The brain was long thought of as a unique, almost privileged organ with its blood-brain barrier preventing harmful substances from gaining access to the brain.  New methods have allowed us to determine that inflammation is present in the brain.  Now we can examine questions such as what precipitates inflammation in the brain in PD and whether the way we address inflammation influences disease progression.” 

Each grant was peer-reviewed and selected by the NPF’s Clinical and Scientific Advisory Board, led by Dr. Deutch. In addition to this grant funding, NPF continues to fund the Parkinson’s Outcomes Project; the largest clinical study of its kind that is currently tracking more than 8,000 people with Parkinson’s who receive care at 21 NPF Centers of Excellence in four countries. For more information about NPF’s research initiatives, visit

Funding is made possible by readers like you. Please consider helping support our efforts to help people beat Parkinson's today.

Wednesday, November 4, 2015
Parkinson’s Foundation Adds John D. Thomopoulos to its Board of Directors
Monday, March 19, 2018

MIAMI & NEW YORK – March 19, 2018 – The Parkinson’s Foundation today announced the election of John D. Thomopoulos to its board of directors. Thomopoulos is a partner at Ernst & Young.

In Memory of Edythe Kay Marsa
Monday, March 12, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member, Edythe (Edy) Kay Marsa. From 1993 to 2014, she was a member of the Foundation’s board of directors and served on several committees. Edy is survived by her husband William Marsa, who founded the Herbert Kay Parkinson Chapter in honor of her first husband who passed away due to complications from Parkinson’s disease.

Parkinson’s Foundation Announces New Genetic Initiative Connecting Parkinson’s Genetic Data with Clinical Care
Tuesday, March 6, 2018

MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network.

Delegates From The Parkinson’s Community Converge On Capitol Hill To Advocate For Critical Research Funding
Monday, March 5, 2018

—2018 Parkinson’s Policy Forum Co-Sponsored by the Parkinson’s Foundation and the Michael J. Fox Foundation for Parkinson’s Research—

Parkinson’s Foundation Appoints Jena E. Abernathy to Board of Directors
Tuesday, February 27, 2018

MIAMI – February 27, 2018 –  The Parkinson’s Foundation today announced the election of Jena E. Abernathy to its board of directors.

Parkinson’s Foundation Moving Day Walks Fund Local Parkinson’s Programs in Seven Cities for Spring 2018
Friday, February 16, 2018

NEW YORK & MIAMI, FEBRUARY 16, 2018 — The Parkinson’s Foundation is proud to announce that Moving Day, A Walk for Parkinson’s, has funded more than $17 million in mission services to make life better for people living with Parkinson’s disease (PD).

Terranova’s Stephen Bittel Donates $450,000 to Parkinson’s Foundation to Support Expansion of Centers of Excellence Network
Thursday, February 1, 2018

MIAMI – February 1, 2018 – The Parkinson’s Foundation today announced that Stephen Bittel, chairman and founder of Terranova, has made a $450,000 donation to support the expansion of the foundation’s Centers o

Largest Clinical Study of Parkinson’s Disease Reaches 10,000-Patient Milestone, Reveals Critical Learnings
Wednesday, January 10, 2018

NEW YORK & MIAMI - January 10, 2018 - The Parkinson’s Foundation today announced the enrollment of the 10,000th Parkinson’s patient and the discovery of critical new learnings in what represents the largest clinical study of Parkinson’s disease in history.

Parkinson's Foundation Mourns the Loss of Harold P. Kravitz and His Daughter, the Honorable Shelley J. Kravitz
Friday, January 5, 2018

Today we mourn the loss of two prominent figures in the history of the Parkinson's Foundation: Harold P. Kravitz, Esq. and his daughter, the Honorable Shelley J. Kravitz.

Parkinson's Foundation Mourns the Loss of Robert Burke, MD
Friday, January 5, 2018

The Parkinson’s Foundation mourns the loss of Robert Burke, MD, professor of Neurology at Columbia University, a Parkinson’s Foundation Center of Excellence. He was a former member of the Parkinson’s Disease Foundation (PDF) Scientific Advisory Board and led the PDF Research Center at Columbia.


mail icon

Subscribe to get the latest news on treatments, research and other updates.